Study outcome won't sway company on eye drug
Wednesday, August 27, 2008 - 13:35
in Health & Medicine
(AP) -- What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000? In the case of Genentech Inc., nothing.
Read the whole article
See latest science articles from Physorg
Latest Science Newsletter
Get the latest and most popular science news articles of the week in your Inbox!Related
- Treatment outcomes highlight dangers of extensively drug-resistant tuberculosisWed, 6 Aug 2008, 17:28:59 EDT
- Free drug samples may end up costing uninsured moreFri, 5 Sep 2008, 6:22:24 EDT
- Promising early evidence of the superior benefits of drug therapy for diabetic eye diseaseWed, 30 Apr 2008, 14:58:02 EDT
- HIV drug maraviroc effective for drug-resistant patientsWed, 1 Oct 2008, 18:07:48 EDT
- What is the best strategy for treating Helicobacter pylori?Tue, 23 Sep 2008, 11:38:09 EDT